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ABSTRACT 
Objective: This study aimed to characterize the physicochemical properties, including pH, zeta potential, and particle size of propranolol-loaded 
nanoparticles that were incorporated into a buccal transmucosal drug-delivery system. 
Methods: An ionotropic gelation technique was used to formulate propranolol-loaded chitosan nanoparticles. Chitosan used as the nanoparticle 
base, using tripolyphosphate (TPP) as a cross-linking agent. The effects on nanoparticle physical properties, including pH, zeta potential, and 
particle size were examined when various chitosan [0.150-0.300 % (w/v)] and propranolol contents (0-40 mg) were used during the preparation. 
The effects of using chitosan solutions with different pH values on nanoparticle properties were also determined.  
Results: The pH values of all nanoparticles ranged between 4.14–4.55. The zeta potentials of the prepared nanoparticles ranged between 22.6–52.6 mV, 
with positive charges. The nanoparticle sizes ranged from 107–140 nm, which are within the range of suitable particle sizes for transmucosal preparations. 
Conclusion: The pH values, zeta potentials, and particle sizes of the nanoparticle formulations were influenced by the concentrations of chitosan 
and propranolol and by the pH of the initial chitosan solution. The relationships between nanoparticle properties and all factors primarily 
depended on the ionic charges of the components, especially chitosan. Our study provides beneficial physicochemical knowledge for the further 
development of chitosan-based nanoparticles containing propranolol for buccal drug delivery systems.  
Keywords: Nanoparticles, Chitosan, Propranolol, Buccal, Drug delivery system, Ionic gelation 
© 2020 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
DOI: http://dx.doi.org/10.22159/ijap.2020v12i4.38009. Journal homepage: https://innovareacademics.in/journals/index.php/ijap  
 
INTRODUCTION 
Nanoparticles have been researched considerably in pharmaceutical 
fields for their potential to carry drugs or active substances directly 
to target sites, due to their intrinsic properties to control drug 
release, to protect drugs from hazardous environments, and to 
increase drug absorption and permeation through mucosal 
membranes [1, 2]. The buccal mucosa is an attractive target site for 
the systemic delivery of drug-loaded nanoparticles to avoid first-
pass metabolism and drug degradation in the gastrointestinal tract 
[3-6]. Various natural polymers have been used to improve the cell 
permeation of buccal drug delivery, including chitosan, alginate, 
agarose, and gums [7]. Chitosan is a popular polymer due to 
intrinsic properties, including low toxicity, biocompatibility, 
biodegradability, mucoadhesion, and membrane permeability [3, 8]. 
Chitosan facilitates the penetration of drugs, using both transcellular 
and paracellular transportation through the mucus membrane [4, 9, 
10]. Transcellular transport occurs through epithelial cell 
transcytosis. For the paracellular route, the positive charges on 
chitosan interact with negatively charged mucus components, 
resulting in the reorganization of the tight junction, which opens the 
epithelial junction [10, 11]. However, chitosan not only interacts 
with negatively charged mucus but hydrophobic and hydrogen 
bonding are also involved [3]. In addition to enhancing drug 
penetration, chitosan has also examined as a potential carrier for 
targeted drug therapies. The activity of an anticancer preparation (a 
mixture of fluorouracil and quercetin) against pancreatic cancer 
cells increased when delivered directly to targeted cells using 
chitosan nanoparticles. The surface amine groups of chitosan 
nanoparticles facilitated the quick uptake of both drugs into the 
cancer cell [12]. Additionally, the cationic chitosan molecules that 
are used to prepare the nanoparticles can interact with anionically 
charged small molecules. Several methods have been described to 
prepare nanoparticles using chitosan, such as ionotropic gelation, 
coprecipitation, microemulsion, emulsification solvent diffusion, 
solvent evaporation, and reverse micellar methods [4,13]. 
Ionotropic gelation is one of the most common techniques for the 
generation of nanoparticles used for drug incorporation, which 
involves an ionic interaction between the positive charges of 
chitosan and the negative charges of polyanion molecules, such as 
tripolyphosphate (TPP) [14, 15]. Ionotropic gelation is a simple 
technique and has many advantages, such as mild conditions, 
preparation in aqueous environments, and low toxicity [4].  
Propranolol, a non-selective-β-adrenergic antagonist, has been used 
for the treatment of cardiovascular disorders, including hypertension, 
cardiac arrhythmia, and angina pectoris [16]. The primary problem 
associated with the oral administration of conventional propranolol 
tablets is the first-pass metabolism. The absorption of propranolol via 
the gastrointestinal tract generally occurs rapidly and nearly 
completely soon after ingesting the drug. However, low bioavailability 
(25%) has been reported due to high first-pass metabolism [1, 17]. To 
solve this problem, the nanoparticle-based formulations of 
propranolol have been developed [1, 18, 19]. Only a few reports have 
characterized propranolol-loaded nanoparticles. Duangjit et al. 
reported the effects of different chitosan molecular weights and 
propranolol concentrations on the physical properties of nanoparticles 
[19]. However, no comprehensive information is currently available 
regarding the effects of propranolol concentrations on nanoparticle 
properties, covering the range of doses that are currently available in 
commercial tablet forms, and the effects of the initial chitosan solution 
pH have not been previously reported. 
To optimize the nanoparticle formulations, the characteristic 
properties of nanoparticles should be determined. In this study, we 
characterized propranolol-loaded chitosan nanoparticles in terms of 
pH, zeta potential, and nanoparticle size. Additionally, the effects of 
altering the chitosan solution pH on the nanoparticle properties 
were also evaluated.  
MATERIALS AND METHODS 
Materials  
Chitosan (MW 20 kDa, 85% degree of deacetylation) was obtained 
from Seafresh Chitosan Lab. Co (Bangkok, Thailand). Propranolol 
HCl was purchased from PC drug Co. Ltd. (Bangkok, Thailand). All 
other chemicals used were of analytical grade and used as received. 
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Preparation of nanoparticles 
Propranolol-loaded chitosan nanoparticles were prepared using the 
ionotropic gelation technique [19]. Seven concentrations of chitosan 
solutions [0.150, 0.175, 0.200, 0.225, 0.250, 0.275, and 0.300% 
(w/v)] were dissolved in a 1% (v/v) acetic acid solution by adding 10 
ml of the chitosan solution and continuously stirring, using a 
magnetic stirrer at room temperature. Different concentrations of 
propranolol (10, 20, 30, and 40 mg in 1 ml of water) were 
individually mixed into the chitosan solution. After the mixture was 
stirred for 5 min, 5 ml 0.1% TPP aqueous solution was added, and 
the mixture was stirred an additional 5 min to form the 
nanoparticles. To examine the effects of the chitosan solution pH on 
the formation of nanoparticles, the pH values of the chitosan 
solutions (pH 3, 3.5, 4, 4.5, 5, 5.5, and 6) was adjusted using 2.0 N 
HCl or 2.0 N NaOH, to reach the desired pH, before the addition of 
propranolol and TPP. Nanoparticles were then investigated with 
regard to pH, zeta potential, and particle size.  
Physicochemical properties the nanoparticles 
The pH values of the nanoparticle were measured using a pH meter 
(Mettler Toledo seven easy, Switzerland). The zeta potentials of the 
nanoparticles were evaluated using a zeta potential analyzer, Zeta 
Plus (Brookhaven Instruments Co., New York, NY, USA). The samples 
were dispersed in distilled water, with gentle stirring, at a volume 
ratio of approximately 1:50 before the experiment [19]. The particle 
sizes of the nanoparticles were determined using the dynamic light 
scattering technique (Horiba, LA-950, Kyoto, Japan), and 
nanoparticles were dispersed in distilled water, with gentle stirring 
before measurement [19]. Each experiment was performed in 
triplicate. 
Statistical analysis 
The experiments were performed in triplicate. The data were compared 
by one-way analysis of variance (ANOVA), using IBM SPSS statistics V26 
software. Data were determined to be significant at p<0.05.  
RESULTS AND DISCUSSION 
Effects of chitosan and propranolol concentrations on the 
physicochemical properties of nanoparticles 
Propranolol-loaded nanoparticles were prepared using the 
ionotropic gelation technique. The chitosan, containing positively 
charged amino groups, was cross-linked to the negatively charged 
TTP. To develop suitable nanoparticles for a buccal propranolol 
delivery system, the physicochemical properties of various 
nanoparticle formulas were evaluated. The characterization of the 
nanoparticles, including pH values, zeta potential, and particle sizes, 
were performed. The nanoparticle formulations were composed of 
chitosan at seven concentrations [0.150–0.300 % (w/v)] and five 
levels of propranolol (0, 10, 20, 30, and 40 mg). The observed pH 
values of the nanoparticles ranged between 4.14–4.55, as shown in 
fig. 1. The pH values of the nanoparticles increased in a chitosan 
concentration-dependent manner. At the same concentrations of 
chitosan, the pH values of the nanoparticles increased slightly with 
higher propranolol concentration. Therefore, the pH values were 
determined to primarily be influenced by the basicity amino moiety 
of the chitosan. 
  
 
Fig. 1: Effect of chitosan and propranolol concentrations on the pH values of the nanoparticles (mean±SD, n=3) 
 
 
Fig. 2: Effect of chitosan and propranolol concentrations on the zeta potential of the nanoparticles (mean±SD, n=3) 
 
The zeta potential of the nanoparticle reveals the surface potential 
difference between the dispersion medium and the dispersed 
particle. Zeta potential is used to determine whether the 
nanoparticle is stable within the dispersed system, as the surface 
charge prevents the aggregation of nanoparticles [20]. The zeta 
potentials of the prepared nanoparticles ranged between 22.6–52.6 
mV, with positive charges (fig. 2). Due to the pH effects shown in fig. 
1, all nanoparticles were acidic, with the pH values below 4.6. In this 
condition, the free amine groups of the chitosan, with pKa values of 
6.5, were protonated; therefore, they exhibited overall positive 
charges [21]. The pKa values of chitosan were demonstrated to 
affect the zeta potential of the nanoparticles [22].  
At the same concentration of chitosan, the zeta potential tended to 
decrease with increasing amounts of propranolol. This result was in 
accordance with a previous study that reported that decreasing zeta 
potentials when propanolol was included at concentrations greater than 
2-fold the concentration of chitosan [1]. Reduced zeta potential with 
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additional drug quantities was also observed in anion drug-loaded 
nanoparticles [10, 23], due to the potential interactions between the 
cations in the chitosan amino groups and the anion in propranolol. 
Therefore, the nanoparticle formation with TPP may be disrupted, 
leading to reduced positive charges on the nanoparticle surface. At fixed 
propranolol concentrations, the zeta potential fluctuated with changing 
chitosan concentrations. However, the zeta potentials of nanoparticles 
containing greater than 0.2% chitosan tended to increase. This result 
agreed with those reported by Al-Kassas et al., who reported that the 
zeta potential increased with increased chitosan concentrations, due to 
the cationic nature of chitosan [1]. 
The effects of different chitosan and propranolol amounts on the 
nanoparticle sizes were also observed using the dynamic light scattering 
technique. Because smaller drugs are taken into the cells in larger 
quantities than larger drugs [24], the goal is to develop the smallest 
particles that can be achieved with good stability. All nanoparticles 
provided similar particle sizes, which ranged from 105–140 nm (fig. 3). 
The smallest nanoparticles were established with the preparation 
containing 0.250% chitosan. Our results were all within the range of 
optimal nanoparticle size of buccal administration, which has been 
reported as approximately 100–300 nm [5], and the particle sizes in our 
study were also smaller than those in previous reports [1, 25]. Although 
the smallest particles were found in the 0.250% chitosan preparation, 
the formulas containing 0.200% and 0.225% chitosan were viewed as 
the optimal concentrations because they produced nanoparticles with 
consistent sizes, which showed no significant differences regardless of 
the propranolol concentration. 
  
 
Fig. 3: Effect of chitosan and propranolol concentrations on the particle size of the nanoparticles (mean±SD, n=3) 
 
Effect of chitosan solution pH on the physicochemical 
properties of nanoparticles 
Due to the presence of free amino groups throughout the chitosan 
structure, the pH environment can affect the ionization of these 
groups, leading to alterations in the ionic crosslinking properties 
associated with nanoparticle formation. Therefore, the effects of 
chitosan solution pH prior to nanoparticle preparation were also 
investigated. The 0.200% (w/v) chitosan solution was chosen, due to 
particle sizes and zeta potential determinations in a varied pH 
environment. The chitosan solution pH value was varied, to 
optimize the nanoparticle stability. The pH values for all 
nanoparticles ranged from 3.53–6.95, with no differences between 
formulations with and without propranolol. The pH values of the 
nanoparticles changed depending on the initial pH value of the 
chitosan solution, as shown in fig. 4. The zeta potentials of 
nanoparticles ranged between 7.50–46.90 mV, with the 
propranolol-loaded samples showing reduced zeta potentials 
compared with nanoparticles containing no drug (fig. 5). The zeta 
potential values of the nanoparticles fluctuated with the increased 
pH of the chitosan solution. However, the addition of the high-pH 
chitosan solution tended to decrease the zeta potential. The decline 
in the zeta potential that is observed with increasing chitosan pH 
values was in agreement with previous results [26, 27], resulting 
from the decreased protonation degree on the chitosan structure 
with increased pH.  
The pH value of the initial chitosan solution also affected the 
nanoparticle size. Altering the pH changes the ionizable groups on 
the chitosan, which changes the electrical network and the swelling 
behavior. As shown in fig. 6, the particle sizes of all nanoparticles 
ranged between 113–681 nm, with the propranolol-loaded 
nanoparticles being smaller than empty nanoparticles. The particle 
sizes reduced when the chitosan pH increased from 3.0 to 4.5. At pH 
values above 4.5, the sizes of the nanoparticles were remarkably 
larger. These results agree with previously described data [26, 28]. 
At low chitosan solution pH values, high degrees of protonated 
amino groups repulse the chitosan molecule, thus causing larger 
particles. The smallest particle sizes were generated using the pH 
4.5 chitosan solutions. Once the pH of chitosan exceeded 4.5, the 
protonation of the amino group decreased, leading to agglomeration 
and the generation of larger particles [26, 28]. 
  
 
Fig. 4: Effect of chitosan solution pH on pH of the nanoparticles (mean±SD, n=3) 
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Fig. 5: Effect of chitosan solution pH on the zeta potential of the nanoparticles (mean±SD, n=3) 
 
 
Fig. 6: Effect of chitosan solution pH on the particle size of the nanoparticles (mean±SD, n=3) 
 
CONCLUSION 
Propranolol-loaded nanoparticles were prepared using the ionic gelation 
technique, with various concentrations of chitosan and propranolol. The 
pH, zeta potential, and particle size of the formulations were 
investigated. The nanoparticle pH varied depending on both the 
concentration and the pH value of the chitosan solution, whereas the 
zeta potential depended only on the amount of propranolol. 
Additionally, the pH of the chitosan solution exhibited effects on 
nanoparticle size. Therefore, we obtained additional useful information 
to support the development of a propranolol-HCl transmucosal delivery 
system. However, drug penetration studies must still be performed to 
confirm the developed formulations. 
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